Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code

QI Yang, ZHOU Yu, SONG Hongtao. Abnormal reduction of valproic acid plasma concentration caused by carbapenem antibiotics[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(4): 369-372. doi: 10.3969/j.issn.1006-0111.2018.04.019
Citation: QI Yang, ZHOU Yu, SONG Hongtao. Abnormal reduction of valproic acid plasma concentration caused by carbapenem antibiotics[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(4): 369-372. doi: 10.3969/j.issn.1006-0111.2018.04.019

Abnormal reduction of valproic acid plasma concentration caused by carbapenem antibiotics

doi: 10.3969/j.issn.1006-0111.2018.04.019
  • Received Date: 2017-08-25
  • Rev Recd Date: 2018-01-04
  • Objective To discuss the risk factors affecting the metabolism of valproic acid (VPA),improve the rational medication and reduce the rate of epilepsy recurrence. Methods Two hospitalized patients were analyzed after being administrated VPA for epilepsy prevention or treatment,with serum VPA levels less than 1 μg/ml. The relevant reasons in literature review in many aspects were collected by clinical pharmacists,such as drugs interaction,hepatic drug-metabolizing cytochrome P450 (CYP) enzymes activity and genetic polymorphism. Results The reduced serum VPA levels were primarily caused by combination of valproic acid and carbapenem. The co-administration of Phenobarbital and rifamycin sodium,as CYP inducers,promoted the metabolism of valproic acid. In addition,the two patients carried mutant allele of CYP2C19,with middle or low grade of VPA metabolism ability. These indicated the dominant role of the medication interaction and the enhanced CYP450 activity in leading to the reduced VPA serum levels. Conclusion Clinicians should closely monitor the serum VPA concentration and the recurrence of seizures when carbapenem and VPA combined.
  • [1] SINGH A,TREVICK S. The epidemiology of global epilepsy[J]. Neurol Clin,2016,34(4):837-847.
    [2] WANG W,WU J,LI S,et al. Sodium valproate for epilepsy in rural China:an efficacy and safety assessment in primary care[J]. Epilepsy Res,2012,102(3):201-205.
    [3] 孙浩,徐英宏,杨振宇,等. 美罗培南致丙戊酸血药浓度显著降低的案例分析[J]. 中国医院药学杂志,2012,32(20):1651-1653.
    [4] NAGAI K,SHIMIZU T,TOGO A,et al. Decrease in serum levels of valproic acid during treatment with a new carbapenem,panipenem/betamipron[J]. J AntimicrobChemother,1997,39(2):295-296.
    [5] MANCL EE,GIDAL BE. The effect of carbapenem antibiotics on plasma concentrations of valproic acid[J]. Ann Pharmacother,2009,43(12):2082-2087.
    [6] YOOH H,KIM DH. Unusual drug reaction between valproate sodium and meropenem[J]. Int J Clin Pharm,2013,35(3):316-318.
    [7] PARK MK,LIM KS,KIM TE,et al. Reduced valproic acid serum concentrations due to drug interactions with carbapenem antibiotics:overview of 6 cases[J]. Ther Drug Monit,2012,34(5):599-603.
    [8] WU CC,PAI TY,HSIAO FY,et al. The effect of different carbapenem antibiotics (ertapenem,imipenem/cilastatin,and meropenem) on serum valproic acid concentrations[J]. Ther Drug Monit,2016,38(5):587-592.
    [9] WEN ZP,FAN SS,DU C,et al. Drug-drug interaction between valproic acid and meropenem:a retrospective analysis of electronic medical records from neurosurgery inpatients[J]. J Clin Pharm Ther,2017,4(2):221-227.
    [10] CHEN YI,GOLDSTEIN JA. The transcriptional regulation of the human CYP2C genes[J]. Curr Drug Metab,2009,10(6):567-578.
    [11] 闫佳佳,何秋毅. 丙戊酸钠血药浓度监测结果与影响因素分析[J].海峡药学,2014(8):151-152.
    [12] 闫彩萍,郝润喜,孙美珍,等. 癫痫患儿联用苯巴比妥、丙戊酸钠时血药浓度分析[J]. 山西医科大学学报,2003,34(1):59-61.
    [13] HANRATH MA,SWART EL. Convulsions due to an interaction between anti-epileptic drugs and rifampicin[J]. Ned Tijdschr Geneeskd,2014,158:A7707.
    [14] 陈珲,蔡泓敏,冯端浩,等. CYP2C9和CYP2C19基因多态性对药物代谢的影响及个体化用药研究进展[J]. 中国药物应用与监测,2014,(4):240-244.
    [15] 韩瑞玲,李艳,吴薇. 癫痫患者CYP2C19基因多态性对丙戊酸钠血药浓度的影响[J]. 神经损伤与功能重建,2015,10(4):295-297.
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Article Metrics

Article views(3981) PDF downloads(529) Cited by()

Related
Proportional views

Abnormal reduction of valproic acid plasma concentration caused by carbapenem antibiotics

doi: 10.3969/j.issn.1006-0111.2018.04.019

Abstract: Objective To discuss the risk factors affecting the metabolism of valproic acid (VPA),improve the rational medication and reduce the rate of epilepsy recurrence. Methods Two hospitalized patients were analyzed after being administrated VPA for epilepsy prevention or treatment,with serum VPA levels less than 1 μg/ml. The relevant reasons in literature review in many aspects were collected by clinical pharmacists,such as drugs interaction,hepatic drug-metabolizing cytochrome P450 (CYP) enzymes activity and genetic polymorphism. Results The reduced serum VPA levels were primarily caused by combination of valproic acid and carbapenem. The co-administration of Phenobarbital and rifamycin sodium,as CYP inducers,promoted the metabolism of valproic acid. In addition,the two patients carried mutant allele of CYP2C19,with middle or low grade of VPA metabolism ability. These indicated the dominant role of the medication interaction and the enhanced CYP450 activity in leading to the reduced VPA serum levels. Conclusion Clinicians should closely monitor the serum VPA concentration and the recurrence of seizures when carbapenem and VPA combined.

QI Yang, ZHOU Yu, SONG Hongtao. Abnormal reduction of valproic acid plasma concentration caused by carbapenem antibiotics[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(4): 369-372. doi: 10.3969/j.issn.1006-0111.2018.04.019
Citation: QI Yang, ZHOU Yu, SONG Hongtao. Abnormal reduction of valproic acid plasma concentration caused by carbapenem antibiotics[J]. Journal of Pharmaceutical Practice and Service, 2018, 36(4): 369-372. doi: 10.3969/j.issn.1006-0111.2018.04.019
Reference (15)

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return